Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11552)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 18, 2016 (publication date) through May 23, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Abbas Z, Memon MS, Umer MA, Abbas M, Shazi L. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial. World J Hepatol 2016; 8(14): 625-631 [PMID: 27190579 DOI: 10.4254/wjh.v8.i14.625] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v8/i14/625.htm |
| Number | Citing Articles |
| 1 |
Alexander J. Stockdale. Comprehensive Guide to Hepatitis Advances. 2023; : 281 doi: 10.1016/B978-0-323-98368-6.00027-6
|
| 2 |
Jun Zi, Xiuzhu Gao, Juan Du, Hongqin Xu, Junqi Niu, Xiumei Chi. Multiple Regions Drive Hepatitis Delta Virus Proliferation and Are Therapeutic Targets. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.838382
|
| 3 |
Maurizia Rossana Brunetto, Gabriele Ricco, Francesco Negro, Heiner Wedemeyer, Cihan Yurdaydin, Tarik Asselah, George Papatheodoridis, Liana Gheorghe, Kosh Agarwal, Patrizia Farci, Maria Buti. EASL Clinical Practice Guidelines on hepatitis delta virus. Journal of Hepatology 2023; 79(2): 433 doi: 10.1016/j.jhep.2023.05.001
|
| 4 |
Hsien‐Hong Lin, Shih‐Jer Hsu, Sheng‐Nan Lu, Wan‐Long Chuang, Chao‐Wei Hsu, Rong‐Nan Chien, Sien‐Sing Yang, Wei‐Wen Su, Jaw‐Ching Wu, Tzong‐Hsi Lee, Cheng‐Yuan Peng, Kuan‐Chiao Tseng, Albert Qin, Yi‐Wen Huang, Pei‐Jer Chen. Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. JGH Open 2021; 5(8): 929 doi: 10.1002/jgh3.12613
|
| 5 |
Onur Keskin, Cihan Yurdaydin. Emerging drugs for hepatitis D. Expert Opinion on Emerging Drugs 2023; 28(2): 55 doi: 10.1080/14728214.2023.2205639
|
| 6 |
Yong Chuan Tan, Guan Huei Lee, Daniel Q. Huang, Seng Gee Lim. Future anti‐HDV treatment strategies, including those aimed at HBV functional cure. Liver International 2023; 43(6): 1157 doi: 10.1111/liv.15387
|
| 7 |
Frédéric Le Gal, Ségolène Brichler, Tudor Drugan, Chakib Alloui, Dominique Roulot, Jean‐Michel Pawlotsky, Paul Dény, Emmanuel Gordien. Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains. Hepatology 2017; 66(6): 1826 doi: 10.1002/hep.29574
|
| 8 |
Olga Metin, Müjdat Zeybel, Cihan Yurdaydin. Treatment endpoints for chronic hepatitis D. Liver International 2023; 43(S1): 60 doi: 10.1111/liv.15447
|
| 9 |
Olympia E. Anastasiou, Florin A. Caruntu, Manuela G. Curescu, Kendal Yalcin, Ulus S. Akarca, Selim Gürel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George V. Papatheodoridis, Onur Keskin, Kerstin Port, Monica Radu, Mustafa K. Celen, Ramazan Idilman, Benjamin Heidrich, Ingmar Mederacke, Heiko von der Leyen, Julia Kahlhöfer, Maria von Karpowitz, Svenja Hardtke, Markus Cornberg, Cihan Yurdaydin, Heiner Wedemeyer. Five‐year follow‐up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D. Liver International 2024; 44(1): 139 doi: 10.1111/liv.15745
|
| 10 |
Rebecca Mercedes, Daniel H. Leung. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 2025; : 1450 doi: 10.1016/B978-0-323-82763-8.00157-6
|
| 11 |
Nathalie Mentha, Sophie Clément, Francesco Negro, Dulce Alfaiate. A review on hepatitis D: From virology to new therapies. Journal of Advanced Research 2019; 17: 3 doi: 10.1016/j.jare.2019.03.009
|
| 12 |
Milan J. Sonneveld, Suzanne van Meer. Encyclopedia of Virology. 2021; : 217 doi: 10.1016/B978-0-12-814515-9.00104-1
|
| 13 |
Vincent Soriano, Kenneth E. Sherman, Pablo Barreiro. Hepatitis delta and HIV infection. AIDS 2017; 31(7): 875 doi: 10.1097/QAD.0000000000001424
|
| 14 |
Mariantonietta Pisaturo, Antonio Russo, Pierantonio Grimaldi, Salvatore Martini, Nicola Coppola. Current and future therapeutic options for chronic hepatitis D virus infection. Frontiers in Cellular and Infection Microbiology 2025; 14 doi: 10.3389/fcimb.2024.1382017
|
| 15 |
Pierre Khalfi, Patrick T. Kennedy, Karim Majzoub, Tarik Asselah. Hepatitis D virus: Improving virological knowledge to develop new treatments. Antiviral Research 2023; 209: 105461 doi: 10.1016/j.antiviral.2022.105461
|
| 16 |
Aigerim Abdrakhman, Aiymkul Ashimkhanova, Wassim Y. Almawi. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis. Antiviral Research 2021; 185: 104995 doi: 10.1016/j.antiviral.2020.104995
|
| 17 |
Lisa Sandmann, Heiner Wedemeyer. Interferon‐based treatment of chronic hepatitis D. Liver International 2023; 43(S1): 69 doi: 10.1111/liv.15410
|
| 18 |
Natali Abeywickrama-Samarakoon, Jean-Claude Cortay, Paul Dény. The hepatitis D satellite virus of hepatitis B virus: half-opening a new era to control viral infection?. Current Opinion in Infectious Diseases 2016; 29(6): 645 doi: 10.1097/QCO.0000000000000321
|
| 19 |
Kali Zhou, Norah A. Terrault. Hepatitis B Virus and Liver Disease. 2021; : 339 doi: 10.1007/978-981-16-3615-8_15
|
| 20 |
Carla S. Coffin, Norah A. Terrault. Hepatitis B Virus and Liver Disease. 2018; : 239 doi: 10.1007/978-981-10-4843-2_13
|
| 21 |
Tomoyuki Hayashi, Yumie Takeshita, Yvan J.-F. Hutin, Hande Harmanci, Philippa Easterbrook, Sarah Hess, Judith van Holten, Ena Oghenekaro Oru, Shuichi Kaneko, Cihan Yurdaydin, Marc Bulterys. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?. Archives of Public Health 2021; 79(1) doi: 10.1186/s13690-021-00693-2
|
| 22 |
Olympia E. Anastasiou, Heiner Wedemeyer. Liver Immunology. 2020; : 287 doi: 10.1007/978-3-030-51709-0_18
|
| 23 |
Andrew Vaillant. Should alanine aminotransferase flares mean stopping antiviral therapy in patients with cirrhosis?. The Lancet Infectious Diseases 2019; 19(3): 221 doi: 10.1016/S1473-3099(18)30686-8
|
| 24 |
Noemi Hernández-Alvarez, Juan Manuel Pascasio Acevedo, Enrique Quintero, Inmaculada Fernández Vázquez, María García-Eliz, Juan de la Revilla Negro, Javier Crespo García, Manuel Hernández-Guerra. Effect of season and sunlight on viral kinetics during hepatitis C virus therapy. BMJ Open Gastroenterology 2017; 4(1): e000115 doi: 10.1136/bmjgast-2016-000115
|
| 25 |
Giuseppina Brancaccio, Giovanni B. Gaeta. Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection. International Journal of Antimicrobial Agents 2019; 54(6): 697 doi: 10.1016/j.ijantimicag.2019.09.012
|